Creative Touch Permanent Makeup and Aesthetics

Rosacea is a chronic inflammatory skin condition affecting the central face, characterised by episodic flushing, persistent erythema, papulopustular lesions, telangiectasia, and in advanced cases phymatous tissue hypertrophy. Its underlying biology is a self-amplifying inflammatory loop driven by dysregulated innate immunity, neurovascular sensitisation, and – in papulopustular presentations – microbial triggering via Demodex-associated bacteria. The four-subtype classification framework is clinically useful for treatment selection but mechanistically incomplete: all subtypes share the same core inflammatory dysregulation, expressed differently depending on which tissue compartments are most affected. Barrier dysfunction is a consistent feature, compounding reactivity to topical products and environmental triggers. Management divides between medical interventions targeting the inflammatory and microbial drivers and aesthetics interventions addressing the vascular and barrier components; both have evidence-supported roles, and neither substitutes for the other.

Rosacea is a chronic, relapsing inflammatory condition of the central facial skin – primarily the cheeks, nose, chin, and forehead – with a pathophysiology rooted in dysregulated innate immune signalling, neurovascular hyperreactivity, and compromised barrier function. It affects an estimated 5–10% of the global population, with higher prevalence in fair-skinned individuals of Northern European ancestry, and presents predominantly in adults aged 30–60. Its chronic and progressive character is not incidental to its biology – it is a direct consequence of the self-amplifying inflammatory mechanisms at its core.

What Rosacea Is (and Isn’t)

Rosacea is frequently described primarily as a vascular condition – a characterisation that is accurate in its observable features but incomplete in its mechanistic framing. The flushing and erythema are vascular phenomena, but they are driven by inflammatory and neurogenic signalling rather than primary vascular disease. Understanding rosacea as a dysregulated inflammatory amplification loop, with vascular and barrier consequences, is more useful for treatment reasoning than the conventional framing of “sensitive, reactive skin with a tendency to flush.”

Two differentiations are worth establishing clearly. First, rosacea is not acne, despite sharing the papulopustular presentation of one of its subtypes. Acne involves comedone formation from follicular obstruction and sebaceous hypersecretion; rosacea papulopustular lesions involve no comedones and arise from inflammatory infiltrates rather than follicular pathology. The sebaceous changes in rosacea – most visible in phymatous presentations – involve fibrotic hypertrophy of sebaceous tissue, not the hypersecretion that characterises acne. Treating rosacea with acne-directed products (benzoyl peroxide, high-concentration salicylic acid) typically worsens the condition by further disrupting a barrier already structurally compromised. Second, the standard four-subtype model (erythematotelangiectatic, papulopustular, phymatous, ocular) describes clinical phenotypes – what rosacea looks like at different stages and in different tissue compartments – but does not map cleanly to four distinct disease mechanisms. All four subtypes share the same core inflammatory dysregulation; the subtype presentation reflects which aspects of that dysregulation are most expressed, not which disease the patient has. ^[2]

The Self-Amplifying Inflammatory Loop

The central mechanism of rosacea pathogenesis is a positive feedback loop involving the serine protease KLK5, the antimicrobial peptide LL-37, and the innate immune activation they sustain in each other. Understanding this loop explains the defining characteristic of rosacea that no trigger-avoidance strategy can fully resolve: once established, the inflammatory state becomes self-perpetuating independent of ongoing external provocation. ^[7]

The sequence operates as follows. KLK5 (kallikrein 5) is a serine protease expressed in the epidermis that cleaves inactive cathelicidin precursor (hCAP18) into its active form, LL-37. In normal skin, KLK5 activity and LL-37 production are tightly regulated. In rosacea-affected skin, KLK5 activity is elevated and LL-37 is produced at substantially higher concentrations – and in an abnormal proteolytic form that is more pro-inflammatory than the LL-37 found in healthy skin. ^[5] Elevated LL-37 activates mTORC1 signalling in keratinocytes, which promotes further cathelicidin expression – closing the first loop. LL-37 simultaneously activates mast cells, which release MMP-9 ( matrix metalloproteinase 9); MMP-9 further processes KLK5 into its active form, amplifying the KLK5 → LL-37 signal from a second direction.

The downstream consequences of sustained LL-37 elevation are what produce rosacea’s clinical features: LL-37 drives VEGF ( vascular endothelial growth factor) expression, promoting angiogenesis and the telangiectasia of erythematotelangiectatic rosacea; it activates the NLRP3 inflammasome, producing IL-1β and IL-18 that sustain the chronic inflammatory state; and it stimulates the neutrophil infiltrates responsible for papulopustular lesion formation. ^[6] The loop does not require continuous external triggering to maintain itself – which is why rosacea is chronic, why it worsens progressively without intervention, and why trigger avoidance alone is insufficient management once the condition is established.

Neurovascular Dysregulation

The flushing response in rosacea is not simply exaggerated thermoregulatory vasodilation – it is a neurogenic inflammatory event involving sensory nerve sensitisation, neuropeptide release, and mast cell activation through pathways that are distinct from normal vascular thermoregulation. This distinction matters because it explains both why rosacea triggers converge on a common pathway and why the flush is disproportionate to the provocation. ^[3]

TRPV1 (the vanilloid receptor covered in the Irritant Lip Plumping Agents entity in a different context) is expressed on cutaneous sensory nerve terminals throughout the facial dermis. In rosacea, TRPV1 is both upregulated in expression and sensitised – its activation threshold is lowered, meaning stimuli that would not activate it in normal skin (mild heat, low concentrations of capsaicin or cinnamaldehyde, moderate alcohol intake, emotional flushing signals) produce full nociceptor activation. TRPV1 activation triggers antidromic release of substance P (SP) and calcitonin gene-related peptide (CGRP) from sensory nerve terminals. These neuropeptides act on local vasculature to produce arteriolar dilation and plasma extravasation, and on mast cells to trigger degranulation – adding a further LL-37-independent route to the inflammatory amplification loop.

This mechanism explains the apparent diversity of rosacea triggers. Spicy food (capsaicin → TRPV1), hot drinks (thermal TRPV1 activation), alcohol (both direct TRPV1 activation and acetaldehyde-mediated vasodilation), UV radiation (TRPV1 sensitisation via reactive oxygen species), emotional stress (sympathetic nervous system → neuropeptide release), and cold wind (paradoxical TRPV1 activation via TRPA1 co-activation at temperature extremes) all converge on the same neuropeptide/mast cell/vascular endpoint. They are not independently different triggers requiring independent management – they are different inputs to the same sensitised pathway.

The Demodex Question

Demodex folliculorum and Demodex brevis – commensal mites resident in sebaceous follicles – are found at higher densities in rosacea-affected skin than in matched controls, and their density correlates with papulopustular severity. The relationship is more mechanistically specific than “Demodex causes rosacea.” ^[1]

The current evidence supports a two-step model: the primary immunogenic trigger is not Demodex itself but Bacillus oleronius – a gram-negative bacterium that lives endosymbiotically within Demodex mites and is released when mites die and lyse within the follicle. B. oleronius proteins are recognised by Toll-like receptors (TLR2 and TLR4) on keratinocytes and dendritic cells, stimulating cathelicidin production and MMP-9 release – feeding directly into the LL-37 loop. Crucially, serum reactivity to B. oleronius proteins has been detected in approximately 79% of papulopustular rosacea patients versus controls, suggesting this is a genuine immunogenic rather than incidental relationship. ^[4] This mechanism provides a mechanistic basis for the efficacy of ivermectin (which reduces Demodex density) in papulopustular rosacea beyond its antiparasitic action – by reducing Demodex load, it reduces B. oleronius release and the consequent TLR-mediated inflammatory stimulus, interrupting the loop from a different entry point than topical antibiotics.

Barrier Dysfunction in Rosacea

Rosacea-affected skin consistently demonstrates elevated TEWL, reduced stratum corneum water content, and reduced expression of filaggrin and claudin-1 – the same structural proteins whose suppression is central to atopic dermatitis barrier failure and covered in their respective entities. ^[2] Whether barrier dysfunction is a cause or consequence of the rosacea inflammatory process remains genuinely contested in the literature. LL-37 itself damages tight junctions and disrupts lamellar lipid organisation, suggesting the inflammatory loop degrades the barrier as a downstream consequence; but several genetic studies have found structural barrier gene variants in rosacea patients, raising the possibility that barrier compromise precedes and facilitates the initial inflammatory sensitisation.

The honest position is that it is likely both: an initially permeable barrier allows greater penetration of environmental triggers and microbial antigens that can initiate TRPV1 sensitisation and TLR activation, and the resulting inflammatory loop then further damages the barrier in a self-reinforcing cycle. The clinical implication is practical regardless of which direction causality runs: barrier support is a therapeutic priority in rosacea management, not an adjunct to it. Clients with rosacea who use harsh cleansers, high-concentration chemical exfoliants, or occlusive products containing known irritants are removing the one structural defence their skin can partially compensate with, at the same time as the inflammatory loop is already undermining it from below.

Subtypes: Clinical Distinctions That Matter

The four-subtype framework is retained here not as a taxonomy of different diseases but as a practical guide to which tissue compartments are most affected and what that implies for management:

Erythematotelangiectatic (ETR) is the predominant vascular expression of rosacea – flushing, persistent central facial erythema, telangiectasia, and stinging sensitivity. The VEGF-driven angiogenesis of the LL-37 loop is most visible here. Vascular laser and IPL (intense pulsed light) target the telangiectatic vessels directly and are the most evidence-supported aesthetic interventions for this subtype. Barrier support is critical; reactive ingredients worsen the sensitisation cycle.

Papulopustular shares the vascular features of ETR but adds inflammatory papules and pustules from neutrophil infiltration. The Demodex/B. oleronius pathway is most clinically relevant here. Medical management (topical metronidazole, azelaic acid, topical or oral ivermectin) is the primary intervention; aesthetics treatments are adjunctive rather than primary in active papulopustular phases.

Phymatous represents the fibrotic endpoint of chronic rosacea – sebaceous tissue hypertrophy and fibrosis producing thickened, irregular skin texture, most commonly rhinophyma (nose). This is not predominantly an inflammatory presentation in its established form; it is a structural tissue change that has moved beyond the inflammatory phase it arose from. Surgical and ablative interventions are the appropriate management. This subtype is not amenable to conservative topical or aesthetic treatment in established cases.

Ocular rosacea affects an estimated 50–60% of rosacea patients at some point and is frequently underdiagnosed in aesthetics consultations. It presents with lid margin telangiectasia, blepharitis, meibomian gland dysfunction, and in severe cases corneal involvement. Clients presenting with concurrent dry eye symptoms, lid inflammation, or recurrent styes alongside facial rosacea should be directed toward ophthalmological assessment rather than assuming the eye symptoms are unrelated. ^[2]

Clinical Context: Aesthetics and Medical Management

Rosacea management divides naturally between what medical treatment addresses and what aesthetics can contribute – and the two are most effective when sequenced rather than substituted.

Medical management targets the inflammatory and microbial drivers: topical azelaic acid suppresses KLK5 activity and LL-37 production directly; topical metronidazole has anti-inflammatory and some antimicrobial activity; oral ivermectin reduces Demodex density and B. oleronius load; low-dose doxycycline (subantimicrobial dose) has anti-inflammatory rather than antibiotic primary action, suppressing MMP-9 and IL-1β production. Clients with active papulopustular or phymatous rosacea, or with ocular involvement, require medical assessment before or alongside aesthetics intervention.

Aesthetics contributions are most appropriate for the vascular and barrier dimensions of rosacea once inflammatory activity is controlled or in mild presentations. IPL and vascular laser target telangiectasia and persistent erythema through selective photothermolysis of haemoglobin – reducing the visible vascular component without addressing the underlying inflammatory driver. Cold atmospheric plasma (CAP) has a directly relevant mechanism here: by suppressing IL-4, IL-13 and reducing the pro-inflammatory cytokine environment, it addresses the inflammatory loop at a signalling level rather than treating symptoms. For clients with rosacea-associated barrier disruption – sensitised, reactive skin that struggles to tolerate standard skincare – CAP’s barrier-restoring action is the primary value, creating conditions in which both the skin’s own repair mechanisms and topical interventions can function more effectively.

Clinical Pearl The single most common aesthetics error in rosacea management is treating the vascular presentation without stabilising the inflammatory environment first. Applying IPL or laser to skin in an active inflammatory phase reduces visible vessels whilst the ongoing LL-37/mast cell loop generates new ones. The sequence – reduce inflammation, support barrier, then address vascular residual – produces more durable results than addressing the visible end-point alone.

Skincare guidance for rosacea-affected clients follows from the mechanism: fragrance-free, low-ingredient formulations that support rather than challenge the barrier; avoidance of high-concentration AHAs, benzoyl peroxide, and TRPV1-activating ingredients ( menthol, capsaicin, high-dose niacinamide at concentrations that produce flushing in sensitised skin); SPF as a non-negotiable daily step given UV’s role as a TRPV1 sensitiser and LL-37 inducer; and temperature-controlled application of products where possible to avoid thermal TRPV1 activation during the skincare routine itself.